Sugi Predict

Sugi Predict / Compounds / SCHEMBL17019

SCHEMBL17019

SCHEMBL17019

CCOc1ccc(C(=O)c2cc(Br)ccc2Cl)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.65
▸ NPSR1 Q6W5P4 2/20 0.65
▸ MAPT P10636 6/20 0.58
▸ ALDH1A1 P00352 6/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ HTT P42858 2/20 0.58
▸ GAA P10253 2/20 0.58
▸ POLB P06746 2/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ SLC5A2 P31639 1/20 0.54
▸ HPGD P15428 3/20 0.51
▸ ALOX15 P16050 2/20 0.51
▸ RECQL P46063 2/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ PTGES O14684 1/20 0.50
▸ CHRNA7 P36544 3/20 0.49
▸ TAS1R3 Q7RTX0 1/20 0.49
▸ TAS1R1 Q7RTX1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29809563 1.00 KDM4E (0.65) KDM4ENPSR1MAPTALDH1A1KMT2A
Methyl Alcohol SCHEMBL28904252 0.99 KDM4E (0.64) KDM4ENPSR1MAPTALDH1A1KMT2A
SCHEMBL17073831 0.86 MAPT (0.54) KDM4ENPSR1MAPTALDH1A1KMT2A
SCHEMBL15494592 0.84 KDM4E (0.67) KDM4ENPSR1MAPTALDH1A1KMT2A
SCHEMBL29022659 0.84 PTGES (0.68) KDM4ENPSR1MAPTALDH1A1KMT2A
SCHEMBL17941 0.84 MAPT (0.52) KDM4ENPSR1MAPTALDH1A1KMT2A
SCHEMBL30504802 0.84 PTGES (0.68) KDM4ENPSR1MAPTALDH1A1KMT2A
SCHEMBL13259887 0.84 NPSR1 (0.48) KDM4ENPSR1MAPTALDH1A1KMT2A
SCHEMBL1457144 0.84 KMT2A (0.63) NPSR1MAPTALDH1A1KMT2AMEN1
SCHEMBL29505229 0.84 KDM4E (0.51) KDM4ENPSR1MAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059809-A Preparation method of dapagliflozin impurity 重庆圣华曦药业股份有限公司 2026-05-19 — — CN claimed
CN-115445242-B Device and method for treating dapagliflozin intermediate mother liquor 浙江工业大学 2024-03-01 — — CN claimed
CN-114544850-B Dapagliflozin intermediate and impurity detection method 苏州正济医药研究有限公司 2023-10-20 — — CN claimed
CN-116354799-A Preparation method of dapagliflozin intermediate 江苏阿尔法药业股份有限公司 2023-06-30 — — CN claimed
CN-116262690-A Synthesis method of (5-bromo-2-chlorophenyl) (4-ethoxyphenyl) methanone 苏州小栗医药科技有限公司 2023-06-16 — — CN claimed
EP-4161912-A1 PREPARATION OF HIGHLY PURE AMORPHOUS DAPAGLIFLOZIN KRKA, d.d., Novo mesto (SI) 2023-04-12 — — EP claimed
CN-115867538-A Preparation of highly pure amorphous dapagliflozin 新梅斯托克公司 2023-03-28 — — CN claimed
CN-115445242-A Treatment device and method for dapagliflozin intermediate mother liquor 浙江工业大学 2022-12-09 — — CN claimed
CN-217248929-U (5-bromo-2-chlorophenyl) (4-ethoxyphenyl) ketone preparation facilities 河南科来福化工有限公司 2022-08-23 — — CN claimed
CN-114544850-A Detection method for dapagliflozin intermediate and impurity 苏州正济医药研究有限公司 2022-05-27 — — CN claimed
CN-107311847-B Preparation method of 5-bromo-2-chloro-4' -ethoxy diphenylmethane 安徽省诚联医药科技有限公司 2020-11-10 — — CN claimed
CN-111662166-A Preparation method of 5-bromo-2-chloro-4' -ethoxy diphenylmethane 吴赣药业（苏州）有限公司 2020-09-15 — — CN claimed
CN-111099975-A Preparation method of 5-bromo-2-chloro-4' -ethoxy benzophenone 河北合佳医药科技集团股份有限公司 2020-05-05 — — CN claimed
US-20170029398-A1 PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-{4-CHLORO-3-4[(4-ETHOXYPHENYL)METHYL]PHENYL]-GLUCITOL AND ITS SOLVATE THEREOF MSN LABORATORIES PRIVATE LIMITED (IN) 2017-02-02 — — US claimed
EP-3114115-A2 PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-[4-CHLORO-3-[(4-ETHOXYPHENYL)METHYL]PHENYL]-D-GLUCITOL AND ITS SOLVATE THEREOF MSN Laboratories Private Limited (IN) 2017-01-11 — — EP claimed
WO-2015132803-A2 PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-[4-CHLORO-3-[(4-ETHOXYPHENYL)METHYL]PHENYL]-D-GLUCITOL AND ITS SOLVATE THEREOF MSN LABORATORIES PRIVATE LIMITED (IN) 2015-09-11 — — WO claimed
CN-122059809-A Preparation method of dapagliflozin impurity 重庆圣华曦药业股份有限公司 2026-05-19 — — CN disclosed
CN-122059809-A Preparation method of dapagliflozin impurity 重庆圣华曦药业股份有限公司 2026-05-19 — — CN disclosed
US-6515117-B2 Sodium dependent glucose transporters found in the intestine and kidney (SGLT2); treating diabetes; compound dapagliflozin BRISTOL-MYERS SQUIBB COMPANY 2003-02-04 — — US disclosed
US-20020137903-A1 C-aryl glucoside SGLT2 inhibitors and method ASTRAZENECA AB (SE) 2002-09-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170029398-A1 PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-{4-CHLORO-3-4[(4-ETHOXYPHENYL)METHYL]PHENYL]-GLUCITOL AND ITS SOLVATE THEREOF ADH1C, ALG1, UGGT1 KDM4E 505/4885NPSR1 4160/4885MAPT 2110/4885
US-20020137903-A1 C-aryl glucoside SGLT2 inhibitors and method SLC5A2, SLC5A1, UGGT1 KDM4E 2579/4885NPSR1 3255/4885MAPT 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.